Protean’s Rapid Lung Test
Full coverage of NCCN recommended variants for lung cancer, with results delivered in 2-3 business days.
View Sample TRF > | Contact us to request Sample Report
Protean’s Rapid Lung Testing is:
Easy – Protean obtains tissue specimens and performs testing in our CAP CLIA laboratory
Simple to Order – Secure electronic portal with bi-directional communication with the Protean laboratory
Fast – Complete lung results within 2-3 business days (as compared to an average of 17 days for NGS¹)
Evidence-based – Follows standard testing guidelines
Effective – Uncovers actionable information in over 90% of cases
Affordable – Covered by most insurance
For newly diagnosed NSCLC patients, the National Cancer Comprehensive Network (NCCN) guidelines recommend testing for alterations in nine genes to determine eligibility for targeted therapies. Molecular testing can detect these clinically relevant biomarkers identified by the NCCN in NSCLC patients, enabling insurance providers to determine eligibility for targeted therapies². Patients with actionable alterations that are treated with targeted therapy have 50% higher survival rates than those who receive chemotherapy or immunotherapy³.
Timely access to biomarker testing can help identify patients who could benefit from targeted therapies, informing treatment decisions that could lead to better patient outcomes and lower healthcare costs.
Coverage of all recommended variants
Standard guidelines recommend testing for variants in nine genes for newly diagnosed NSCLC patients.
The biomarkers covered by Rapid Lung Testing are EGFR, ALK, ROS, RET, METex14, NTRK1/2/3, BRAF, KRAS
DNA Mutations
KRAS
EGFR
BRAF
RNA Gene Fusions
ALK
RET
ROS
METex14
NTRK 1/2/3
IHCs
PD-L1
HER2
HER2 ISH
MET
Rapid Lung – Reliable with High Sensitivity and Specificity
- Strong scientific evidence for use for NSCLC, supported by >50 publications
- Rapid Lung testing shows low failure rates (≤1.5%) 4, 10, 11
- Proven performance and reliability 4, 11
Interested in Rapid Lung Testing?
Fill out your information below and someone will reach out to you to set up an appointment.
References
Kerr et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. Apr 2021
Aggarwal et al. Presented at ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9022
Hendriks et al. on behalf of the ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023.
Behnke et al. FACILITATE A real-world multicenter prospective investigating the utility of fully automated real-time PCR assay versus local reference methods for detecting EGFR variants in NSCLC. Pathology & Oncology Research. Feb 2023
Finall et al. Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of nonsquamous, non-small cell lung cancer (NSCLC) patients with follow-up. J Clin Path. Jan 2022
Hardstock et al. Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis. BMC Cancer. Mar 2020
Sadik et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology. Oct 2022
Wheeldon et al. Use of the Biocartis Idylla™ Platform for the Detection of Epidermal Growth Factor Receptor, BRAF and KRAS Proto-Oncogene Mutations in Liquid-Based Cytology Specimens from Patients with Non-Small Cell Lung Carcinoma and Pancreatic Adenocarcinoma. J Mol Pathology. May 2022
Gregg et al. Molecular testing strategies in non-small cell lung cancer: Optimizing the diagnostic journey. Transl Lung Cancer Res. Jun 2019
Arcila et al. Ultra-Rapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: A Feasible, Informative Approach for Lung Carcinoma Cytology Specimens with a High Success Rate. JTO Clinical and Research Reports. Jul 2020
Chu et al. Clinical utility and performance of an ultra-rapid multiplex RNA-based assay for detection of ALK, ROS1, RET and NTRK1/2/3 rearrangements and MET exon 14 skipping alterations. J Mol Diag. Apr 2022
